{
    "nctId": "NCT05580887",
    "briefTitle": "Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients",
    "officialTitle": "Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Pancreas Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 35,
    "primaryOutcomeMeasure": "Intestinal bacterial structure in BC and PnC (separately) patients with disease progression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* untreated early HR+ HER2- BC:\n\n  1. planned neoadjuvant chemotherapy: dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles\n  2. TanyN1-3M0 Ki67\\>40% G3\n  3. ECOG 0-1\n* untreated early HR+ HER2- BC:\n\n  1. TanyN0M0 Ki67\\<20% G1\n  2. ECOG 0-1\n  3. planned induction endocrine therapy (letrozole/anastrazole/tamoxifen)\n* untreated locally-advanced and/or borderline resectable pancreas cancer:\n\n  1. planned (neo)adjuvant chemotherapy: mFOLFIRINOX\n  2. previous surgery ( only R0 resection) is allowed\n  3. ECOG 0-1\n  4. histology diagnosis verification\n* Informed consent\n* Eligible blood\\&fecal samples and tumor tissue for different time points\n\nExclusion Criteria:\n\n* autoimmune disease\n* active steroid therapy\n* ECOG \\> 2\n* any previous therapy for breast cancer\n* metastatic cancer\n* antibiotic use less than 28 days\n* other tumor",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}